J1303 HCPCS code: Injection, ravulizumab-cwvz, 10 mg
J1303 is the HCPCS Level II code for injection, ravulizumab-cwvz, 10 mg. In 2024 Medicare paid an average of $171.57 per service for J1303 across 1,230,566 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 360 per day on outpatient hospital claims. Medicare volume rose 223% from 2022 to 2024 (380,589 to 1,230,566 services). In 2024, about 937 clinicians billed Medicare for J1303 for 808 beneficiaries; Texas, Florida, Illinois accounted for 33% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-10-01 |
| Last action effective | 2019-10-01 |
Who bills J1303 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 937 |
| Medicare beneficiaries | 808 |
| States with claims | 25 |
| Share of services in top 3 states (Texas, Florida, Illinois) | 33% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1303, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 380,589 | 337 | $218.36 | $174.12 |
| 2023 | 891,341 | 616 | $216.17 | $172.22 |
| 2024 | 1,230,566 | 808 | $215.36 | $171.57 |
States with the most J1303 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 146,608 | $173.17 |
| Florida | 145,444 | $170.30 |
| Illinois | 71,211 | $173.45 |
| Tennessee | 62,512 | $171.01 |
| California | 60,469 | $172.96 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 360 | Prescribing Information |
| practitioner claims | 360 | Prescribing Information |
What changed for J1303
- 2019-10-01: J1303 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1303?
J1303 is the HCPCS Level II code for injection, ravulizumab-cwvz, 10 mg. Short descriptor: "Inj., ravulizumab-cwvz 10 mg".
How much does Medicare pay for J1303?
In 2024, the average Medicare payment was $171.57 per service (average allowed $215.36).
Does Medicare cover J1303?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J1303 can be billed per day?
360 on outpatient hospital claims; 360 on practitioner claims (NCCI medically unlikely edits).
Related J13 codes
- J1300 — Injection, eculizumab, 10 mg
- J1301 — Injection, edaravone, 1 mg
- J1302 — Injection, sutimlimab-jome, 10 mg
- J1304 — Injection, tofersen, 1 mg
- J1305 — Injection, evinacumab-dgnb, 5mg
- J1306 — Injection, inclisiran, 1 mg
- J1307 — Injection, crovalimab-akkz, 10 mg
- J1308 — Injection, famotidine, 0.25 mg
- J1320 — Injection, amitriptyline hcl, up to 20 mg
- J1322 — Injection, elosulfase alfa, 1 mg
- J1323 — Injection, elranatamab-bcmm, 1 mg
- J1324 — Injection, enfuvirtide, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1303
- Watch J1303 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1303
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.